Amgen Inc
Change company Symbol lookup
Select an option...
AMGN Amgen Inc
BOSC BOS Better Online Solutions Ltd
BORR Borr Drilling Ltd
BOOT Boot Barn Holdings Inc
EPD Enterprise Products Partners LP
$JSEMET EMIX Smaller Europe Metal Production
CUB Cubic Corp
FB Facebook Inc
NWVCF Enwave Corp

Health Care : Biotechnology | Large Cap Value
Company profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Closing Price
Day's Change
3.83 (1.58%)
B/A Size
Day's High
Day's Low
(Above Average)

10-day average volume:

UPDATE: FuelCell's stock has rallied too much to keep recommend buying, analyst says

7:44 am ET November 20, 2020 (MarketWatch)

Tomi Kilgore

J.P. Morgan's Paul Coster downgrades FuelCell six weeks after initiating at overweight, as stock trades well above his fair value estimate

Shares of FuelCell Energy Inc. kept rising Thursday, even after J.P. Morgan analyst Paul Coster backed away from his bullish call on the fuel cell technology and power generation company, following the "dramatic" run up this week on no news.

The stock (FCEL) shot up as much as 17.5% to an intraday high of $5.99, before pulling back to close up 5.1% in active trading, the highest close since March 6, 2019. It has rocketed 109.4% amid a five-day win streak. Trading volume swelled to 210.95 million shares, more than five times the full-day average of about 33.6 million shares.

The shares have soared 133.0% over the past month, which Coster pegs initially on a wave of regional "climate ambition" initiatives associated with hydrogen and fuel cells, then on a re-rating of alternative energy stocks on the back of Joe Biden's victory in the presidential election.

But the "more dramatic" move over the past several days seemed to take place in the absence of any new news, he said.

Don't miss: FuelCell's stock doubles in 4 days on increasing volume (

Coster cut his rating on FuelCell to neutral, after initiative it at overweight six weeks ago. He raised his stock fair value estimate to "around $4," which is 25.4% below current levels, from about $3.

"Fundamentals do seem good for [FuelCell], and the company seems to be on a track for profitability in 2022, but the stock has traded through our prior estimate for fair value," Coster wrote in a note to clients.

He said his new neutral rating "is not a call to sell the stock," which he said embeds "significant optionality" associated with carbon capture and the hydrogen economy, he just prefers other names in his coverage universe at this time.

Specifically, in the fuel cell/hydrogen space, Coster said he prefers Bloom Energy Corp. (BE), which he has rated overweight since August 2018.

Meanwhile, Coster said FuelCell's stock remains "somewhat attractive" relative to those of Plug Power Inc. (PLUG) and Ballard Power Systems Inc. (BLDP.T)

FuelCell's stock has run up 81.1% over the past three months, while Bloom Energy shares have advanced 14.7% and the S&P 500 index has gained 5.8%.

-Tomi Kilgore; 415-439-6400;

(END) Dow Jones Newswires

November 20, 2020 07:44 ET (12:44 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.